A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) As Add on Therapy in Patients with Advanced/metastatic Solid Tumors Treated by Standard Immunotherapies

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NP 137 (Primary) ; Programmed cell death-1 ligand-1 modulators
Indications Solid tumours
Focus Proof of concept; Therapeutic Use
Acronyms IMMUNONET

Most Recent Events

29 Nov 2022 Status changed from not yet recruiting to recruiting, according to a Netris Pharma media release.
29 Nov 2022 According to a Netris Pharma media release, first patient has been dosed.
10 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight